Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma

Lymphoma
26/08/2020

BMJ Case Rep. 2020 Aug 25;13(8):e235578. doi: 10.1136/bcr-2020-235578.

ABSTRACT

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodulator that has shown safety and efficacy in multiple myeloma and is also approved for use in several types of lymphoma. In the case described here, the patient had a significant partial response to lenalidomide, which has not previously been described in this


type of lymphoma. Given how aggressive and difficult to treat ALK+ LBCL is, further research is warranted to more completely elucidate the mechanism of action of lenalidomide in ALK+ LBCL and its role in treatment.